Healthcare-focused private equity fund Tata Capital Healthcare Fund II (TCHF II) announced that it has invested an amount of USD 20 million in Orbicular Pharmaceutical Technologies Private Limited ...

Orbicular Pharmaceutical Technologies has agreed to resolve its patent fight with Theravance Biopharma (NASDAQ:TBPH) and Viatris (NASDAQ:VTRS) unit, Mylan, over the respiratory disorder therapy ...

MUMBAI: (May 31) Tata Capital on Friday said one of its arms has invested USD 20 million in Orbicular Pharmaceutical Technologies for an undisclosed stake. Tata Capital Healthcare Fund II has made the ...

Orbicular, a specialty pharmaceutical company focused on research and product development, will use its expertise in drug delivery and formulation to develop nasal sprays for global markets.